Table 2.
Clinical characteristics of patients at baseline.
| Characteristic | All patients (n = 198) | |
|---|---|---|
| n | % | |
| Age, years | ||
| Median | 61 | |
| Range | 32–86 | |
| ≤65 | 135 | 68.2 |
| >65 | 63 | 31.8 |
| Stage | ||
| IIIB/IIIC | 4 | 2 |
| IV | 194 | 98 |
| Pathology type | ||
| Adenocarcinoma | 168 | 84.9 |
| Squamous carcinoma | 8 | 4 |
| Others | 22 | 11.1 |
| Gender | ||
| Male | 116 | 58.6 |
| Female | 82 | 41.4 |
| Smoking history | ||
| Never smoker | 105 | 53 |
| Ever smoker | 93 | 47 |
| Genotype | ||
| EGFR | 98 | 49.5 |
| ALK | 16 | 8.1 |
| E/A-negative driver genes* | 49 | 24.7 |
| Pan-negative# | 35 | 17.7 |
| TMB | ||
| Median | 5.6 | |
| Range | 0–25.8 | |
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; TMB, tumor mutation burden.
*
E/A-negative driver genes: EGFR/ALK negative driver mutations, including BRAF/HER2/KRAS/NRAS/MET//ROS1/RET.
#
Pan-negative: tumors that lack mutations in known targetable genes.